newsfilter
← Latest News
Business Wire·

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

  • AN2 Therapeutics granted inducement equity awards to newly-appointed Chief Medical Officer Cameron Trenor, M.D.
  • The awards consist of 233,333 non-qualified stock options & 116,667 restricted stock units.
  • Stock options have an exercise price of $5.36 per share, a 10-year term, & vest over four years.
  • 25% of option shares vest on August 24, 2026, with the remainder vesting monthly thereafter.
  • 10,400 restricted stock units vest on January 1, 2027, with the remainder vesting in three equal annual installments starting January 1, 2028.
  • Vesting for all awards is subject to continued employment through the applicable dates.
  • Awards were approved by the Compensation Committee on September 15, 2026, under the 2026 Employment Inducement Award Plan.
  • AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics from its boron chemistry platform.
  • The company has three Phase 2 studies expected to be active in 2026 across hematologic diseases, infectious diseases, & oncology.